press center press release

Dr. Samuel Waxman, Scientific Director of the Samuel Waxman Cancer Research Foundation and SWCRF Chairman, Michael Nierenberg to Ring the NASDAQ Stock Market Closing Bell

Published

ADVISORY, Nov. 24, 2006 (PRIMEZONE) --

What: Dr. Samuel Waxman, Scientific Director of Samuel Waxman Cancer Research Foundation (SWCRF) and SWCRF Chairman, Michael Nierenberg, will preside over the closing bell to celebrate the Ninth Annual Collaborating for a Cure Benefit to be held on November 30th at the Metropolitan Pavilion in New York City. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Monday, November 27, 2006 at 4:00 p.m. ET Contacts: Barbara Hutson 646.644.0560; (mobile) 917.856.2872 hutson@witsendmedia.com NASDAQ MarketSite: Jolene Libretto; 646.441.5220

Feed Information:

The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About the Samuel Waxman Cancer Research Foundation:

For 30 years, the SWCRF has been instrumental in developing new drugs to successfully treat cancer, and has trained and supported more than 160 scientists by awarding them with over $55 million in grants. Based at the Mt. Sinai Medical Center in New York City, the Foundation funds highly collaborative basic translational and clinical research groups throughout the United States, Canada, China, Israel and Europe. Presently, 50 scientists work within SWCRF's "Institute Without Walls" with emphasis on breast, lung, liver and prostate cancer, blood malignancies and melanoma.

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more